Details for Patent: 11,384,086
✉ Email this page to a colleague
Which drugs does patent 11,384,086 protect, and when does it expire?
Patent 11,384,086 protects ICLUSIG and is included in one NDA.
This patent has thirty-seven patent family members in nine countries.
Summary for Patent: 11,384,086
| Title: | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
| Abstract: | Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein. |
| Inventor(s): | Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma |
| Assignee: | Takeda Pharmaceuticals USA Inc |
| Application Number: | US17/318,876 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,384,086 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 11,384,086
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-004 | Dec 18, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA | ⤷ Start Trial | ||
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-004 | Dec 18, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN | ⤷ Start Trial | ||
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-004 | Dec 18, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA | ⤷ Start Trial | ||
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-001 | Dec 14, 2012 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA | ⤷ Start Trial | ||
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-001 | Dec 14, 2012 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA | ⤷ Start Trial | ||
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-001 | Dec 14, 2012 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,384,086
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013204506 | ⤷ Start Trial | |||
| Australia | 2016210725 | ⤷ Start Trial | |||
| Australia | 2018201013 | ⤷ Start Trial | |||
| Australia | 2019240721 | ⤷ Start Trial | |||
| Australia | 2021221493 | ⤷ Start Trial | |||
| Australia | 2023219845 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
